GSK and Astrazeneca shares slump as Trump vows drug price cut May 12, 2025 GSK and Astrazeneca shares fall as Trump announces drug price cuts in a new executive order.
FTSE 100’s record run ends as pharma stocks slide on new Trump appointment May 7, 2025 The FTSE 100’s record run came to an end on Wednesday as pharma stocks slumped on the back of a controversial US regulatory appointment. The blue-chip index spent the entire session in the red and closed off 0.4 per cent. Drugmakers GSK and Astrazeneca were among the top fallers, at nearly five per cent and [...]
GSK shares rise as FTSE 100 giant ‘well positioned’ for pharma tariffs April 30, 2025 British drugmaker GSK insisted it was “well positioned” to respond to the impact of sector-specific tariffs amid widespread speculation President Donald Trump is set to target pharmaceutical imports with his tariff agenda. Trump voiced his desire to slap tariffs on pharma products in the “not too distant future”. He previously said: “We don’t make our [...]
Starmer must act now to protect NHS from Trump pharma tariffs April 17, 2025 Starmer must make a deal to avoid Trump's pharma tariffs or risk a major hit to the NHS, write Ben Ramanauskas and Sean Phillips.
UK-India trade deal reportedly 90 per cent agreed, businesses told April 10, 2025 The UK’s trade deal with India is reportedly 90 per cent agreed, businesses have been told, according to a report in the Guardian. Firms were informed on a call with trade negotiators this week that some remaining issues included cars, pharmaceutical drugs and the whisky trade, the newspaper reported, with India currently the largest overseas [...]
Hikma’s profit jumps as demand for generic medicines booms February 26, 2025 Hikma Pharmaceuticals reported a strong financial performance for 2024, with revenue rising nine per cent to $3.13bn (£2.47bn) and operating profit up 67 per cent to $612m (£483m). Profit attributable to shareholders nearly doubled, reaching $359m (£284m), while earnings per share rose 88 per cent. The multinational pharmaceutical company that develops, manufactures, and markets a [...]
Astrazeneca: ‘We’re too big to base our CEO’s pay on FTSE 100 peers’ February 18, 2025 Astrazeneca is too big and complex to base its chief executive’s pay packet on the rest of the FTSE index, according to the chair of its remuneration committee. Writing in the pharmaceutical giant’s annual report, chair Sheri McCoy said “UK-listed FTSE companies are not the right peer group for us to use” given the group’s [...]
Astrazeneca revenue surges amid Chinese import tax allegations February 6, 2025 Astrazeneca’s revenue jumped 21 per cent last year despite growing troubles over its presence in China. The pharmaceutical giant recorded $54bn (£43.3bn) in revenue for the year, a jump of 21 per cent on 2023’s levels. In its full-year results, the largest FTSE 100 firm revealed that revenue in Europe had skyrocketed 37 per cent. [...]
Astrazeneca: FTSE 100 giant shrugs off China worries with profit upgrade November 12, 2024 Pharmaceuticals giant Astrazeneca has reported double-digit sales growth on higher demand and said it remains committed to China despite the detention of a high-ranking staff member there. The FTSE 100 firm told markets this morning that total revenue rose 19 per cent to $39.2bn (£30.6bn) in the first nine months of the year. The London-listed [...]
Support for innovation is needed in Budget warns pharmaceutical industry October 15, 2024 The Association of the British Pharmaceutical Industry (ABPI) has called on Rachel Reeves to prioritise research and development (R&D) investment in the coming Labour Budget to unlock the potential of the UK life sciences sector. The APBI’s pre-Budget submission stressed the importance of maintaining and increasing public R&D funding to increase the UK’s attractiveness as [...]